Literature DB >> 27144467

The clinical spectrum of sporadic and familial forms of frontotemporal dementia.

Ione O C Woollacott1, Jonathan D Rohrer1.   

Abstract

The term frontotemporal dementia (FTD) describes a clinically, genetically and pathologically diverse group of neurodegenerative disorders. Symptoms of FTD can present in individuals in their 20s through to their 90s, but the mean age at onset is in the sixth decade. The most common presentation is with a change in personality and impaired social conduct (behavioural variant FTD). Less frequently patients present with language problems (primary progressive aphasia). Both of these groups of patients can develop motor features consistent with either motor neuron disease (usually the amyotrophic lateral sclerosis variant) or parkinsonism (most commonly a progressive supranuclear palsy or corticobasal syndrome). In about a third of cases FTD is familial, with mutations in the progranulin, microtubule-associated protein tau and chromosome 9 open reading frame 72 genes being the major causes. Mutations in a number of other genes including TANK-binding kinase 1 are rare causes of familial FTD. This review aims to clarify the often confusing terminology of FTD, and outline the various clinical features and diagnostic criteria of sporadic and familial FTD syndromes. It will also discuss the current major challenges in FTD research and clinical practice, and potential areas for future research. This review clarifies the terminology of frontotemporal dementia (FTD) and summarizes the various clinical features and most recent diagnostic criteria of sporadic and familial FTD syndromes. It also discusses the current major challenges in FTD research and clinical practice, and highlights potential areas for future research.
© 2016 International Society for Neurochemistry.

Entities:  

Keywords:  C9ORF72; amyotrophic lateral sclerosis; frontotemporal dementia; progranulin; tau

Mesh:

Substances:

Year:  2016        PMID: 27144467     DOI: 10.1111/jnc.13654

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  43 in total

Review 1.  Speech and language therapy approaches to managing primary progressive aphasia.

Authors:  Anna Volkmer; Emily Rogalski; Maya Henry; Cathleen Taylor-Rubin; Leanne Ruggero; Rebecca Khayum; Jackie Kindell; Maria Luisa Gorno-Tempini; Jason D Warren; Jonathan D Rohrer
Journal:  Pract Neurol       Date:  2019-07-29

2.  Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.

Authors:  Adam M Staffaroni; Lynn Bajorek; Kaitlin B Casaletto; Yann Cobigo; Sheng-Yang M Goh; Amy Wolf; Hilary W Heuer; Fanny M Elahi; Peter A Ljubenkov; Reilly Dever; John Kornak; Brian Appleby; Jessica Bove; Yvette Bordelon; Patrick Brannelly; Danielle Brushaber; Christina Caso; Giovanni Coppola; Christina Dheel; Bradford C Dickerson; Susan Dickinson; Sophia Dominguez; Kimiko Domoto-Reilly; Kelly Faber; Jessica Ferrall; Julie A Fields; Ann Fishman; Jamie Fong; Tatiana Foroud; Leah K Forsberg; Ralitza Gavrilova; Debra Gearhart; Behnaz Ghazanfari; Nupur Ghoshal; Jill Goldman; Jonathan Graff-Radford; Neill Graff-Radford; Ian Grant; Murray Grossman; Dana Haley; Ging-Yuek Hsiung; Edward D Huey; David J Irwin; David T Jones; Lynne Jones; Kejal Kantarci; Anna Karydas; Daniel I Kaufer; Diana R Kerwin; David S Knopman; Ruth Kraft; Walter K Kremers; Walter A Kukull; Irene Litvan; Diane Lucente; Codrin Lungu; Ian R Mackenzie; Miranda Maldonado; Masood Manoochehri; Scott M McGinnis; Emily McKinley; Mario F Mendez; Bruce L Miller; Namita Multani; Chiadi Onyike; Jaya Padmanabhan; Alex Pantelyat; Rodney Pearlman; Len Petrucelli; Madeline Potter; Rosa Rademakers; Eliana Marisa Ramos; Katherine P Rankin; Katya Rascovsky; Erik D Roberson; Emily Rogalski; Pheth Sengdy; Leslie M Shaw; Jeremy Syrjanen; M Carmela Tartaglia; Nadine Tatton; Joanne Taylor; Arthur Toga; John Q Trojanowski; Sandra Weintraub; Ping Wang; Bonnie Wong; Zbigniew Wszolek; Adam L Boxer; Brad F Boeve; Joel H Kramer; Howard J Rosen
Journal:  Alzheimers Dement       Date:  2019-05-11       Impact factor: 21.566

Review 3.  Infectious immunity in the central nervous system and brain function.

Authors:  Robyn S Klein; Charise Garber; Nicole Howard
Journal:  Nat Immunol       Date:  2017-01-16       Impact factor: 25.606

4.  Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.

Authors:  Ione O C Woollacott; Jennifer M Nicholas; Carolin Heller; Martha S Foiani; Katrina M Moore; Lucy L Russell; Ross W Paterson; Ashvini Keshavan; Jonathan M Schott; Jason D Warren; Amanda Heslegrave; Henrik Zetterberg; Jonathan D Rohrer
Journal:  Dement Geriatr Cogn Disord       Date:  2020-04-28       Impact factor: 2.959

Review 5.  [Genetic architecture of amyotrophic lateral sclerosis and frontotemporal dementia : Overlap and differences].

Authors:  M Synofzik; M Otto; A Ludolph; J H Weishaupt
Journal:  Nervenarzt       Date:  2017-07       Impact factor: 1.214

Review 6.  A review on shared clinical and molecular mechanisms between bipolar disorder and frontotemporal dementia.

Authors:  Camila Nascimento; Villela Paula Nunes; Roberta Diehl Rodriguez; Leonel Takada; Cláudia Kimie Suemoto; Lea Tenenholz Grinberg; Ricardo Nitrini; Beny Lafer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2019-04-20       Impact factor: 5.067

Review 7.  Frontotemporal dementia: latest evidence and clinical implications.

Authors:  Juan Joseph Young; Mallika Lavakumar; Deena Tampi; Silpa Balachandran; Rajesh R Tampi
Journal:  Ther Adv Psychopharmacol       Date:  2017-11-10

8.  ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration.

Authors:  Katheryn A Q Cousins; Jeffrey S Phillips; David J Irwin; Edward B Lee; David A Wolk; Leslie M Shaw; Henrik Zetterberg; Kaj Blennow; Sarah E Burke; Nikolas G Kinney; Garrett S Gibbons; Corey T McMillan; John Q Trojanowski; Murray Grossman
Journal:  Alzheimers Dement       Date:  2020-11-23       Impact factor: 21.566

9.  A Case of Frontotemporal Lobar Degeneration With FUS-Positive Pathology (FTLD-FET) With Corticobasal Features and Language Deficits.

Authors:  Vanessa Goodwill; David Coughlin; Donald Pizzo; Douglas Galasko; Lawrence A Hansen; Shauna H Yuan; Annie Hiniker
Journal:  J Neuropathol Exp Neurol       Date:  2021-09-27       Impact factor: 3.685

10.  Frontotemporal Lobar Degeneration TDP-43-Immunoreactive Pathological Subtypes: Clinical and Mechanistic Significance.

Authors:  Manuela Neumann; Edward B Lee; Ian R Mackenzie
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.